Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4

Phase 3Positive

AI Analysis

Phathom Pharmaceuticals forecasts 2026 revenue of $310M-$325M and plans to initiate a Phase 3 as-needed GERD trial in Q4.

Phase

Phase 3

Guidance

$310M-$325M 2026 revenue

Importance:5/10

Sentiment:

0.30

GERDPhase 3 trialrevenue guidanceas-needed treatment

Related Companies

Read the original article

Published by Seeking Alpha Healthcare on July 31, 2026 12:44 AM